PTC Therapeutics | PTCT - Current Assets


PTC Therapeutics reported $2.54B in Current Assets for its fiscal quarter ending in September of 2026.





Current Assets Change Date
Acadia Pharmaceuticals USD 1.27B 43.88M Sep/2026
Alnylam Pharmaceuticals USD 5.11B 492.49M Sep/2026
Amgen USD 34.36B 598M Sep/2026
BioCryst Pharmaceuticals USD 531.15M 46.47M Sep/2026
Biogen USD 7.58B 278.7M Sep/2026
BioMarin Pharmaceutical USD 3.92B 50.99M Sep/2026
Cytokinetics USD 1.19B 21.34M Sep/2026
Daiichi Sankyo JPY 2.38T 150.33B Sep/2026
Enanta Pharmaceuticals USD 198.68M 5.65M Dec/2025
Gilead Sciences USD 16.55B 4.02B Sep/2026
Incyte USD 5.52B 505.2M Sep/2026
Ionis Pharmaceuticals USD 2.36B 129.77M Sep/2026
Ironwood Pharmaceuticals USD 225.99M 26.79M Sep/2026
Karyopharm Therapeutics USD 126.33M 23.19M Mar/2026
Novartis USD 28.75B 1.4B Sep/2026
Pfizer USD 45.01B 3.65B Sep/2026
PTC Therapeutics USD 2.54B 79.58M Sep/2026
Puma Biotechnology USD 143.58M 7M Sep/2025
Roche Holding CHF 35.44B 3.29B Jun/2026
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
Sarepta Therapeutics USD 2.27B 49.06M Sep/2026
TG Therapeutics USD 1.17B 25.76M Sep/2026
Ultragenyx Pharmaceutical USD 544M 62M Sep/2026
Vertex Pharmaceuticals USD 11.69B 857.4M Sep/2026
Xencor USD 498.66M 24.55M Sep/2026